Hims & Hers (HIMS) Surges 13.2% on GLP-1 Regulatory Tailwind
As seen on the 24/7 Wall St. homepage on July 23, 2026.
Hims & Hers Health surged as the telehealth company stands to benefit from ongoing regulatory scrutiny that's keeping compounded GLP-1 competitors off the shelves.
Continue ReadingShow less
Hims & Hers Health opened the session at $31.14 and climbed to $35.24, a gain of roughly 13.2% during regular trading hours. The sharpest part of the move came in a concentrated burst, with the stock vaulting from the low $32 range into the mid-$33s and beyond in a matter of minutes before finding a higher trading range.
The driver, according to the company's market narrative, is continued regulatory scrutiny that is keeping compounded GLP-1 alternatives off pharmacy shelves. Compounded versions of GLP-1 drugs had been positioned as lower-cost competitors to branded obesity and diabetes medications, and any regulatory barrier to those alternatives effectively narrows the competitive landscape for telehealth platforms like Hims & Hers that offer obesity care services.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
For investors watching the stock, the key question going forward is whether the regulatory environment that sparked today's move proves durable. If compounded GLP-1 products remain restricted, Hims & Hers could continue to see patient and revenue tailwinds in its weight-loss offerings. Any shift in the regulatory posture from health authorities would likely reverse that thesis quickly.
Sources
Mentioned: HIMS